Investigational Drug Information for TL-895
✉ Email this page to a colleague
What is the drug development status for TL-895?
TL-895 is an investigational drug.
There have been 7 clinical trials for TL-895.
The most recent clinical trial was a Phase 1 trial, which was initiated on April 13th 2021.
The most common disease conditions in clinical trials are Primary Myelofibrosis, Leukemia, and Lymphoma, Large B-Cell, Diffuse. The leading clinical trial sponsors are Telios Pharma, Inc., Kartos Therapeutics, Inc., and Merck KGaA.
There are five US patents protecting this investigational drug and fifty-nine international patents.
Summary for TL-895
US Patents | 5 |
International Patents | 59 |
US Patent Applications | 21 |
WIPO Patent Applications | 6 |
Japanese Patent Applications | 5 |
Clinical Trial Progress | Phase 1 (2021-04-13) |
Vendors | 11 |
Recent Clinical Trials for TL-895
Title | Sponsor | Phase |
---|---|---|
Phase 1b/2 Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib | Telios Pharma, Inc. | Phase 1/Phase 2 |
Study of KRT-232 or TL-895 in Janus Associated Kinase Inhibitor Treatment-Naïve Myelofibrosis | Kartos Therapeutics, Inc. | Phase 2 |
TL-895 and KRT-232 Study in Acute Myeloid Leukemia | Kartos Therapeutics, Inc. | Phase 1/Phase 2 |
Clinical Trial Summary for TL-895
Top disease conditions for TL-895
Top clinical trial sponsors for TL-895
US Patents for TL-895
Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
---|---|---|---|---|
TL-895 | ⤷ Try a Trial | Compositions and methods for the production of pyrimidine and pyridine compounds with BTK inhibitory activity | Merck Patent GmbH (Darmstadt, DE) | ⤷ Try a Trial |
TL-895 | ⤷ Try a Trial | Compositions and methods for the production of pyrimidine and pyridine compounds with BTK inhibitory activity | Merck Patent GmbH (Darmstadt, DE) | ⤷ Try a Trial |
TL-895 | ⤷ Try a Trial | Methods for treating MS using pyrimidine and pyridine compounds with BTK inhibitory activity | Merck Patent GmbH (Darmstadt, DE) | ⤷ Try a Trial |
TL-895 | ⤷ Try a Trial | Compositions and methods for the production of pyrimidine and pyridine compounds with BTK inhibitory activity | Merck Patent GmbH (Darmstadt, DE) | ⤷ Try a Trial |
TL-895 | ⤷ Try a Trial | Compositions and methods for the production of pyrimidine and pyridine compounds with BTK inhibitory activity | Merck Patent GmbH (Darmstadt, DE) | ⤷ Try a Trial |
>Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for TL-895
Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
---|---|---|---|---|
TL-895 | Australia | AU2012267491 | 2031-06-10 | ⤷ Try a Trial |
TL-895 | Australia | AU2017235978 | 2031-06-10 | ⤷ Try a Trial |
TL-895 | Brazil | BR112013030442 | 2031-06-10 | ⤷ Try a Trial |
TL-895 | Canada | CA2833771 | 2031-06-10 | ⤷ Try a Trial |
TL-895 | China | CN103814016 | 2031-06-10 | ⤷ Try a Trial |
TL-895 | China | CN106831732 | 2031-06-10 | ⤷ Try a Trial |
TL-895 | Denmark | DK2718270 | 2031-06-10 | ⤷ Try a Trial |
>Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |